Medpace Holdings Inc vs Schwab US Dividend Equity ETF — how do they compare? Medpace Holdings Inc trades at $600.79 (market cap $16.90B), while Schwab US Dividend Equity ETF trades at $34.26. Which is the better fit depends on your goals.
| MEDP | SCHD | |
|---|---|---|
Market Cap | $16.90B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $620.59 | $34.27 |
52-Week Low | $393.42 | $26.44 |
Enterprise Value | $16.52B | — |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
SCHD trades at $34.225, up 0.1% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF's dividend strategy remains a core appeal, highlighted by a scheduled $0.25 dividend in June 2026. Recent news emphasizes its role in retirement income portfolios and institutional accumulation, such as Barry Investment Advisors increasing its stake by 29.9% in Q2 2026.
Outlook is supported by dividend reliability and value rotation trends, but risks include yield competition from Treasuries and tax inefficiencies in taxable accounts. The ETF suits income-focused investors seeking steady payouts, though overbought conditions may limit near-term gains.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →